S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
NASDAQ:GERN

Geron (GERN) Stock Price, News & Analysis

$3.45
-0.19 (-5.22%)
(As of 04/15/2024 ET)
Today's Range
$3.40
$3.71
50-Day Range
$1.75
$3.77
52-Week Range
$1.64
$4.05
Volume
11.91 million shs
Average Volume
11.70 million shs
Market Capitalization
$1.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

Geron MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
54.6% Upside
$5.33 Price Target
Short Interest
Healthy
8.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.80
Upright™ Environmental Score
News Sentiment
0.63mentions of Geron in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

264th out of 928 stocks

Pharmaceutical Preparations Industry

117th out of 432 stocks

GERN stock logo

About Geron Stock (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

GERN Stock Price History

GERN Stock News Headlines

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
“Forget Tesla, this is Elon’s Next Big Thing”
According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.
Geron (NASDAQ:GERN) Rating Reiterated by Needham & Company LLC
“Forget Tesla, this is Elon’s Next Big Thing”
According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.
Geron (NASDAQ:GERN) Given Outperform Rating at Wedbush
GERN Mar 2024 3.500 put
GERN Apr 2024 1.000 put
GERN Apr 2024 1.500 call
Geron Corp.
MDGL Apr 2024 270.000 call
Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)
Why Is Geron (GERN) Stock Up 94% Today?
See More Headlines
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/16/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
141
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.33
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+54.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-184,130,000.00
Net Margins
-77,691.14%
Pretax Margin
-77,690.72%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$0.46 per share

Miscellaneous

Free Float
530,468,000
Market Cap
$1.89 billion
Optionable
Optionable
Beta
0.61
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. John A. Scarlett M.D. (Age 73)
    Chairman of the Board, President & CEO
    Comp: $1.53M
  • Dr. Andrew J. Grethlein Ph.D. (Age 60)
    Executive VP & COO
    Comp: $847.2k
  • Ms. Michelle J. Robertson (Age 56)
    Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
  • Ms. Aron Feingold
    Vice President of Investor Relations & Corporate Communications
  • Mr. Scott Samuels
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Ms. Shannon Odam (Age 49)
    Senior VP & Chief People Officer
  • Ms. Melissa A. Kelly Behrs (Age 60)
    Executive VP of Business Operations & Chief Alliance Officer
    Comp: $753.22k
  • Mr. Anil Kapur (Age 53)
    Executive VP of Corporate Strategy & Chief Commercial Officer
    Comp: $654.89k
  • Mr. Edward E. Koval (Age 62)
    Executive VP & Chief Business Officer
  • Dr. Faye Feller M.D. (Age 41)
    Executive VP & Chief Medical Officer

GERN Stock Analysis - Frequently Asked Questions

Should I buy or sell Geron stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price target for 2024?

3 Wall Street analysts have issued 12 month price targets for Geron's stock. Their GERN share price targets range from $5.00 to $6.00. On average, they expect the company's stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2024?

Geron's stock was trading at $2.11 at the beginning of the year. Since then, GERN stock has increased by 63.5% and is now trading at $3.45.
View the best growth stocks for 2024 here
.

Are investors shorting Geron?

Geron saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 46,660,000 shares, a decline of 8.4% from the March 15th total of 50,950,000 shares. Based on an average trading volume of 11,240,000 shares, the days-to-cover ratio is presently 4.2 days.
View Geron's Short Interest
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Geron had a negative net margin of 77,691.14% and a negative trailing twelve-month return on equity of 63.33%. The company's revenue was down 77.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) earnings per share.

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GERN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners